Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+4 more
XTC, Rolls, Beans, Pingers+1 more
Substituted phenethylamineMDA, MDEA, 5-APB +4 moreMDA, MDEA, 5-APB, 6-APB, methylone, mephedrone, amphetamine show less
MDMA
3,4-methylenedioxy-N-methylamphetamine
MDMA (3,4-methylenedioxy-N-methylamphetamine) — ecstasy, molly — is a synthetic empathogen of the substituted amphetamine class. It is the prototypical entactogen — distinct from classical stimulants and psychedelics. It floods the brain with serotonin, norepinephrine, and dopamine, producing emotional warmth rather than stimulant energy.[1][2]
MDMA (3,4-methylenedioxy-N-methylamphetamine) — ecstasy, molly — is a synthetic empathogen of the substituted amphetamine class. It is the prototypical entactogen, distinguished from classical stimulants by its emotional rather than euphoric emphasis. MDMA is a monoamine transporter releaser with serotonin-preferential activity,[1] producing its effects by driving reverse transport of serotonin, norepinephrine, and dopamine.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+4 more
XTC, Rolls, Beans, Pingers+1 more
Substituted phenethylamineMDA, MDEA, 5-APB +4 moreMDA, MDEA, 5-APB, 6-APB, methylone, mephedrone, amphetamine show less
MDMA was first synthesized at Merck in 1912 and rediscovered by Alexander Shulgin in 1976, who introduced it to a network of therapists.[3][4] Recreational spread as "Ecstasy" led to DEA emergency scheduling in 1985. Australia permitted medical prescribing in 2023; the FDA declined approval in 2024, and MDMA remains Schedule I in the United States.[5][6]
Subjective effects include euphoria, intense warmth toward others, sociability enhancement and trust, and mild brightening of perception.[7] The experience is defined by its entactogenic quality — profound emotional openness and closeness to others unlike either stimulant energy or psychedelic expansion. Jaw clenching, elevated heart rate, and a low-mood comedown from serotonin depletion are characteristic unwanted effects.
MDMA produces no physical dependence, though moderate psychological dependence is documented;[8] no human lethal dose has been established. The main dangers — overheating, dangerous sodium imbalance, and serotonin syndrome — multiply sharply in hot environments and when combined with serotonin-active drugs.[2] MDMA is among the most studied psychoactive substances, though how much it damages serotonin-producing nerve cells in humans remains genuinely contested.[9]
History[edit]
Discovery
MDMA was first synthesized on 24 December 1912 by Anton Köllisch at Merck — not as a drug but as a chemical intermediate in a patent dispute over a blood-clotting agent.[3][10] In 1976, Alexander Shulgin developed a new synthesis and introduced MDMA to a network of therapists, who found it produced emotional openness and strengthened the therapeutic relationship.[4]
Clinical and cultural significance
By the early 1980s, hundreds of therapists were using MDMA under the name "Adam." Recreational spread as "Ecstasy" triggered DEA emergency scheduling in 1985. Two Phase 3 clinical trials later demonstrated significant PTSD symptom reduction with large effect sizes, reigniting clinical interest.[11][12]
Prohibition and modern status
MDMA was placed permanently in Schedule I in March 1986.[13] Australia became the first country to authorize medical prescribing in July 2023;[5] the US FDA declined approval in August 2024, citing concerns about study design and safety data.[6]
The name "Ecstasy" was coined as MDMA moved from therapy rooms into nightlife. Therapists had called it "Adam" — evoking a state of primal innocence. "Molly" emerged in the 2000s to suggest pure crystalline MDMA distinct from pressed tablets, though testing shows both vary widely in purity. Animal research published in 1988 finding selective damage to serotonin nerve terminals[14] set the terms of scientific and public debate for nearly four decades.
Chemistry[edit]
Structural class
MDMA belongs to the substituted methylenedioxyphenethylamine family — a group of phenethylamines sharing a 3,4-methylenedioxy ring. The molecular formula is C₁₁H₁₅NO₂ (free base).
Its closest active structural analog is MDA; MDMA's additional N-methyl group makes it more serotonin-selective, producing a more emotionally focused and less perceptually psychedelic experience.
Pharmacology[edit]
Mechanism of action
MDMA enters serotonin, norepinephrine, and dopamine transporters and reverses their function, flooding the synapse with all three neurotransmitters.[2] Unlike cocaine — which blocks reuptake without triggering release — MDMA drives active release.[2] Serotonin is released preferentially over dopamine,[1] producing MDMA's emotional warmth rather than the reward-focused drive of dopamine-preferring stimulants.[2][15]
Oxytocin release
MDMA triggers a large surge of oxytocin — a hormone linked to social bonding — peaking around 90–120 minutes after dosing.[16] Oxytocin alone cannot reproduce the full empathogenic experience,[17] indicating it is one part of a broader mechanism.
Pharmacokinetics
MDMA reaches peak blood levels about 1.5–2 hours after oral ingestion,[15] with a half-life of roughly 7–8 hours.[15][7] Critically, MDMA permanently disables the liver enzyme responsible for breaking it down after just two doses,[18][19] so blood levels rise disproportionately with repeated dosing — greatly increasing overdose risk from redosing.
Neuroscience[edit]
Where it acts
MDMA quiets the amygdala — the brain region that registers threat — reducing recognition of fearful faces[17] and increasing trust and cooperative behavior.[20] Simultaneously, it triggers a large oxytocin surge.[16] The combination of reduced threat sensitivity and heightened social bonding chemistry is thought to explain MDMA's window of therapeutic effectiveness.
Why it matters
The leading explanation for MDMA-assisted therapy centers on memory reconsolidation: traumatic memories are reactivated in a state of reduced fear, then re-stored with an updated emotional tone. MDMA specifically dampens fearful emotional memory while leaving neutral memory intact,[21] providing a biological basis for this process.
Whether MDMA produces lasting changes to brain structure and connectivity — as classical psychedelics may — or simply creates a temporary state that enables therapeutic learning, remains unresolved. Heavy users show reduced SERT availability on brain imaging[22] and small but measurable impairments in memory and cognitive flexibility,[23] though whether these represent permanent damage or reversible adaptation is debated.[9]
Subjective Effects[edit]
MDMA's subjective character is defined by its entactogenic quality — a state of intense emotional openness, warmth toward others, and interpersonal trust that feels pharmacologically distinct from any other drug category. Social settings amplify emotional closeness; stimulating environments bring the drug's energetic side to the foreground.[7]
Compared to amphetamine, MDMA produces comparable physical stimulation but with a marked emotional softening absent from dopamine-preferring stimulants.[24] Compared to MDA, the experience is less perceptually psychedelic and more emotionally focused, with a shorter duration.[2]
Synthesized at Merck in 1912 as a chemical intermediate,[3] MDMA was rediscovered by Alexander Shulgin in 1976.[4] Recreational spread as "Ecstasy" triggered DEA scheduling in 1985; decades later, FDA Breakthrough Therapy Designation for PTSD[5] and two Phase 3 trials with large effect sizes[6][7] reignited clinical interest. Australia permits medical prescribing;[8] the FDA declined approval in 2024[9] and MDMA remains Schedule I in the United States.
Subjective effects include euphoria, empathogenic warmth, enhanced sociability, increased trust, and mild perceptual brightening. The experience is defined by its entactogenic core — a profound emotional openness and interpersonal closeness that feels distinct from both stimulant energy and psychedelic expansion.[10] Jaw clenching, cardiovascular stimulation, and a serotonin-depleted comedown are characteristic unsought effects.
MDMA produces no classical physical dependence, though moderate psychological dependence liability is documented in recreational contexts;[11] no human lethal dose has been established. The primary risks — hyperthermia, water-electrolyte imbalance, and serotonin syndrome — are amplified by hot environments, exertion, and serotonergic drug combinations;[2] nonlinear pharmacokinetics from CYP2D6 inhibition elevate overdose risk with repeated dosing.[12][13] MDMA is among the most studied psychoactive substances, though the extent of long-term serotonergic neurotoxicity in humans remains debated.[14]
History[edit]
Discovery
MDMA was first synthesized on 24 December 1912 by Anton Köllisch at the German pharmaceutical company Merck, recorded in laboratory journals as "Methylsafrylamin".[3][15] Contrary to popular myth, it was not developed as an appetite suppressant but arose as an intermediate in a patent protecting a synthesis route for hydrastinine, a hemostatic agent, to circumvent a competing Bayer patent.[3] In 1976, Alexander Shulgin developed a new synthesis and introduced MDMA to psychologist Leo Zeff, who distributed it to a network of therapists across the US West Coast.[4]
Clinical and cultural significance
By the early 1980s, hundreds of psychotherapists were using MDMA under the name "Adam" as an adjunct valued for producing emotional openness and facilitating the therapeutic alliance. Recreational use spread simultaneously under the name "Ecstasy." The FDA granted Breakthrough Therapy Designation for MDMA-assisted PTSD therapy in 2017,[5] and two Phase 3 trials — MAPP1 and MAPP2 — demonstrated significant symptom reduction with large effect sizes.[6][7]
Prohibition and modern status
The DEA invoked emergency scheduling authority in July 1985, permanently placing MDMA in Schedule I in March 1986.[16] Switzerland permitted therapeutic use from 1988 to 1993.[17] Australia became the first country to authorize medical prescribing in July 2023,[8] while the US FDA declined approval in August 2024, citing concerns about blinding integrity and absent safety assessments.[9]
The name "Ecstasy" was coined in the early 1980s as MDMA moved from therapeutic circles into nightlife. Therapists had used "Adam" — a reference to a state of primal innocence the compound was said to evoke. "Molly," short for "molecule," emerged in the 2000s to suggest pure crystalline MDMA as distinct from pressed tablets, though analytical testing shows both forms vary widely in purity and composition. The neurotoxicity findings published by O'Hearn et al. in 1988[18] — selective serotonergic nerve terminal damage in animal models — established a framework of concern that has shaped scientific debate and public perception for nearly four decades.
Chemistry[edit]
Structural class
MDMA belongs to the substituted methylenedioxyphenethylamine family, a subclass of phenethylamines sharing the 3,4-methylenedioxy ring substitution. The parent scaffold is amphetamine; MDMA adds a 3,4-methylenedioxy bridge on the aromatic ring and an N-methyl group on the nitrogen. This combination distinguishes it from its N-demethylated structural analog MDA, which is also a pharmacologically active metabolite. The methylenedioxy ring defines the "MD-" series of entactogens, which includes MDEA and MBDB. The N-methyl group increases serotonergic selectivity relative to MDA.
Molecular structure
| Molecular formula | C₁₁H₁₅NO₂ |
| Molecular weight | 193.24 g/mol (free base); 229.70 g/mol (HCl salt) |
The molecule consists of a phenethylamine backbone with an α-methyl group (conferring the amphetamine scaffold), an N-methyl substituent on the amine nitrogen, and a 3,4-methylenedioxy bridge fusing positions 3 and 4 of the aromatic ring into a 1,3-dioxole system.
Stereochemistry
MDMA has one chirality center at the α-carbon, producing two enantiomers: S(+)-MDMA and R(−)-MDMA. The substance is used as the racemic mixture in both recreational and clinical contexts.[19][20] S(+)-MDMA is more potent at serotonin and dopamine transporters, produces stronger stimulant and oxytocin-releasing effects, and has a shorter half-life. R(−)-MDMA contributes mild perceptual effects through 5-HT₂A activity and has a substantially longer half-life due to differential metabolism.
Physical properties
The free base is a colorless oil, insoluble in water. The hydrochloride salt — the most common form in pharmaceutical and illicit contexts — is a white crystalline powder with a melting point of 147–153°C, soluble in water and methanol.citation needed
Pharmacology[edit]
Mechanism of action
MDMA enters nerve terminals through the serotonin, norepinephrine, and dopamine transporters (SERT, NET, DAT) and reverses their normal function, driving massive release of all three neurotransmitters into the synapse.[2] This mechanism — substrate-type release — distinguishes MDMA from reuptake blockers like cocaine, which prevent neurotransmitter removal without triggering release.[2]
MDMA's release potency favors serotonin over dopamine,[1] which accounts for its empathogenic and emotionally open character rather than the pure reward-driven euphoria of dopamine-preferring stimulants.[2][21] MDMA also activates TAAR1 (TAAR1), contributing to its monoamine-releasing and stimulant properties.[22]
Blocking studies in 44 healthy volunteers have mapped which receptor systems produce which effects[23]: serotonin release drives most of the subjective experience — mood elevation, extraversion, emotional openness; dopamine mediates euphoria specifically; and 5-HT₂A receptor activation produces MDMA's mild perceptual changes. Serotonin reuptake blockade also reduced cardiovascular effects but not body temperature,[24] suggesting thermoregulation involves mechanisms beyond serotonin release alone.
Oxytocin release
MDMA produces a substantial surge in plasma oxytocin, peaking at roughly four times baseline levels 90–120 minutes after dosing.[25] S-MDMA drives greater oxytocin release than R-MDMA at equivalent doses.[19] This oxytocin response likely contributes to MDMA's prosocial effects, though intranasal oxytocin alone does not replicate the full empathogenic profile,[26] indicating oxytocin is one component of a multi-system mechanism.
Pharmacokinetics
MDMA reaches peak blood levels approximately 1.5–2 hours after oral ingestion.[21] The two enantiomers are eliminated at different rates: S-MDMA has a half-life of approximately 5 hours, while R-MDMA persists for roughly 11 hours.[19] Earlier studies of the racemic mixture reported an overall half-life of 7–8 hours.[21][10]
The liver metabolizes MDMA through two main routes[21]: the primary pathway converts MDMA through the methylenedioxy ring, and a secondary pathway produces the active metabolite MDA.
A critical pharmacokinetic feature is that MDMA irreversibly disables CYP2D6 — the primary enzyme responsible for its own metabolism — after as few as two consecutive doses.[12][13] This means blood levels rise disproportionately with repeated dosing, regardless of baseline metabolizer status. This nonlinear pharmacokinetics is a major contributor to overdose risk from redosing. Recovery of CYP2D6 function shows sex differences.[13]
Neuroscience[edit]
Where it acts
MDMA's effects on the brain center on two systems: the amygdala and the oxytocin pathway. The amygdala's response to threatening stimuli is dampened — recognition of fearful and angry facial expressions decreases,[26] and trust and cooperative behavior increase.[27] Simultaneously, MDMA triggers a substantial oxytocin release,[25] with S-MDMA producing greater release than R-MDMA.[19] The combination — reduced threat sensitivity alongside enhanced social bonding chemistry — is proposed to create the therapeutic window exploited in PTSD treatment.
Why it matters
The leading framework for MDMA-assisted therapy is memory reconsolidation: traumatic memories are reactivated under conditions of reduced fear and enhanced social safety, then stored with updated emotional tone. MDMA selectively impairs emotional memory while sparing neutral recall,[28] providing a pharmacological basis for this process.
The bioenergetic stress model[29] frames MDMA's neurotoxic potential differently — cumulative metabolic strain from monoamine depletion, oxidative stress, and hyperthermia damages serotonergic neurons. This predicts that harm is dose-dependent, temperature-dependent, and pattern-dependent, explaining why controlled clinical use may carry substantially lower risk than recreational binge use in hot environments.
Key unresolved questions include whether MDMA promotes lasting neuroplastic changes analogous to those produced by classical psychedelics, or primarily facilitates state-dependent learning. The dose and frequency required to produce detectable serotonergic damage in humans has not been established — whether clinical-dose MDMA carries any measurable neurotoxic risk is unknown.
Subjective Effects[edit]
MDMA's subjective character is dominated by its entactogenic quality — a state of emotional openness, interpersonal trust, and empathic warmth that is pharmacologically distinct from both psychedelic perception-shifting and stimulant-driven energy. At lower doses the experience leans toward gentle mood elevation and sociability; at higher doses the empathogenic warmth intensifies alongside greater stimulation and mild perceptual effects. Social setting profoundly shapes the experience — intimate environments amplify emotional closeness, while high-stimulation contexts foreground the stimulant component. Ambient temperature is a critical variable, potentiating both subjective intensity and physiological risk.
Compared to amphetamine, MDMA produces comparable physical stimulation but with a pronounced emotional softening absent from dopamine-preferring stimulants.[32] Compared to MDA, MDMA is less perceptually psychedelic and more emotionally focused, with a shorter duration — reflecting its greater serotonergic selectivity.[2]
Effect Grid
At common doses (80–120 mg oral), the full MDMA experience manifests. Pronounced euphoria and emotional warmth dominate — a powerful sense of closeness to others, increased empathy, enhanced trust, and desire for physical and verbal intimacy. Music sounds deeply pleasurable. Emotional barriers feel temporarily dissolved, and difficult topics become approachable.
Physically, stimulation is moderate to strong: jaw clenching (trismus), teeth grinding (bruxism), pupil dilation, increased heart rate and blood pressure, mild nausea on come-up, and temperature dysregulation become common. Sweating increases. Appetite is strongly suppressed.
The core experience lasts 3–5 hours. Sleep is typically impossible for 4–6 hours after effects resolve. A period of low mood, fatigue, and reduced motivation ("comedown") commonly follows over 1–2 days.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Sound sensitivity · Color enhancement · Taste enhancement · Visual haze / noise · Tracers · Auditory distortion · Brightness alteration · Color alteration · Light sensitivity · Sleep-transition hallucinations · Visual acuity enhancement · Auditory misinterpretation · Depth perception distortion · Peripheral vision distortion · Perspective distortion · Proprioceptive distortion · Spatial disorientation · Synesthesia · Tinnitus · Vestibular distortion · Olfactory enhancement · Peripheral misidentification · Symmetrical texture repetition · After-images · Flashbacks · External hallucinations · Internal hallucinations · Auditory hallucinations
Tracers · Auditory distortion · Brightness alteration · Color alteration · Light sensitivity · Sleep-transition hallucinations · Visual acuity enhancement · Auditory misinterpretation · Depth perception distortion · Peripheral vision distortion · Perspective distortion · Proprioceptive distortion · Spatial disorientation · Synesthesia · Tinnitus · Vestibular distortion · Olfactory enhancement · Peripheral misidentification · Symmetrical texture repetition · After-images · Flashbacks · External hallucinations · Internal hallucinations · Auditory hallucinations
Spontaneous body sensations · Stimulation · Body high · Physical fatigue · Tactile euphoria · Dry mouth · Excessive sweating · Pupil dilation · Bruxism · Muscle tension · Insomnia · Tingling / electric sensations · Dehydration sensation · Abnormal heartbeat · Bodily lightness · Heart rate perception changes · Laughter fits · Nystagmus (eye wobbles) · Restlessness · Headache · Pain suppression · Sedation · Sexual arousal enhancement · Respiratory stimulation · Nausea · Sexual arousal suppression · Breathing alteration · Vibrations / buzzing · Motor control enhancement · Brain zaps · Bodily pressures · Dizziness · Motor control impairment · Muscle relaxation · Trembling · Watery eyes · Seizure threshold reduction · Salivation · Body schema distortion · Constipation · Involuntary body movements · Nasal congestion · Yawning · Increased urination · Diarrhea · Vomiting
Physical fatigue · Tactile euphoria · Dry mouth · Excessive sweating · Pupil dilation · Bruxism · Muscle tension · Insomnia · Tingling / electric sensations · Dehydration sensation · Bodily lightness · Heart rate perception changes · Laughter fits · Nystagmus (eye wobbles) · Restlessness · Headache · Pain suppression · Sedation · Sexual arousal enhancement · Respiratory stimulation · Nausea · Sexual arousal suppression · Breathing alteration · Vibrations / buzzing · Motor control enhancement · Brain zaps · Bodily pressures · Dizziness · Motor control impairment · Muscle relaxation · Trembling · Watery eyes · Seizure threshold reduction · Salivation · Body schema distortion · Constipation · Involuntary body movements · Nasal congestion · Yawning · Increased urination · Diarrhea · Vomiting
Immersion enhancement · Aesthetic enhancement · Introspection enhancement · Thought acceleration · Cognitive impairment · Motivation suppression · Cognitive flexibility · Suggestibility enhancement · Humor enhancement · Cognitive dysphoria · Novelty enhancement · Thought connectivity · Motivation enhancement · Language enhancement · Pattern recognition enhancement · Creativity enhancement · Analysis enhancement · Conceptual thinking · Focus suppression · Memory suppression · Focus enhancement · Information processing enhancement · Thought disorganization · Confusion · Increased nature relatedness · Information processing suppression · Memory fragmentation · Memory replays · Thought loops · Thought organization · Thought deceleration · Synchronicity · Amnesia · Delirium
Thought acceleration · Cognitive impairment · Motivation suppression · Cognitive flexibility · Humor enhancement · Cognitive dysphoria · Novelty enhancement · Thought connectivity · Motivation enhancement · Language enhancement · Pattern recognition enhancement · Creativity enhancement · Analysis enhancement · Conceptual thinking · Focus suppression · Memory suppression · Focus enhancement · Information processing enhancement · Thought disorganization · Confusion · Increased nature relatedness · Information processing suppression · Memory fragmentation · Memory replays · Thought loops · Thought organization · Thought deceleration · Synchronicity · Amnesia · Delirium
Euphoria · Irritability · Catharsis · Emotional lability · Simultaneous emotions · Anhedonia · Dysphoria · Anxiety · Mania · Suicidal ideation
Emotional lability · Simultaneous emotions · Anhedonia · Dysphoria · Anxiety · Suicidal ideation
Emotional susceptibility · Communication enhancement · Sociability enhancement · Craving · Flow state · Social disconnection · Derealization · Ego inflation · Compulsive behavior reduction · Depersonalization · Boundary dissolution · Telepathic feelings · Ego dissolution
Flow state · Social disconnection · Derealization · Ego inflation · Compulsive behavior reduction · Depersonalization · Boundary dissolution · Telepathic feelings · Ego dissolution
Timeline
First alerts appear 30–45 minutes after ingestion: a subtle shift in mood, mild physical warmth, and faint butterflies in the stomach. Effects are easily missed if distracted.
Effects build rapidly over 15–30 minutes. Mood elevation accelerates, jaw tension begins, pupil dilation becomes noticeable, and a rush of warmth and sociability emerges. Brief nausea or anxiety is common during this phase.
Maximum intensity is sustained for 1. 5–2. 5 hours.
Effects gradually diminish over 1–1. 5 hours. Emotional warmth persists but stimulation fades.
The comedown unfolds over 1–1. 5 hours. Residual stimulation gives way to fatigue.
Aftereffects persist 12–48 hours. The first 24 hours often bring fatigue, low mood, reduced appetite, and difficulty concentrating — commonly called the "comedown" or "suicide Tuesday" among weekly users. Some individuals report a paradoxical afterglow of emotional openness and reflectiveness.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- rapid
- Tolerance reset
- 75 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- MDA · MDEA · 5-APB
Toxicity
Acute toxicity
No human lethal dose has been established. MDMA has been given to more than 1,100 people in clinical trials at doses up to 180 mg without drug-related serious adverse events.[25]
Hyperthermia
Overheating is the primary cause of severe MDMA toxicity. MDMA disrupts temperature regulation through multiple pathways, and hot environments, physical exertion, and crowded spaces dramatically worsen this effect.[2][26] Sustained dancing in hot venues is the most common setting for fatal overheating.
Hyponatremia
MDMA causes the body to retain water by triggering abnormal hormone release. Combined with excessive water drinking, this dilutes blood sodium to dangerous levels and can cause the brain to swell.[27][28]
Suspected water intoxication — confusion or altered consciousness after MDMA use — requires urgent medical attention. Treatment involves controlled saline and fluid restriction.[28]
Liver toxicity
MDMA can cause liver damage appearing days to weeks after use, sometimes independent of dose. Cases of acute liver failure requiring transplantation have been reported in young users.[29]
Heart and circulation
MDMA raises blood pressure and heart rate and constricts blood vessels, including coronary arteries. These effects worsen substantially with overheating. Phase 3 clinical trials found no dangerous heart rhythm changes.[11]
Serotonin syndrome
High doses or combinations with serotonin-active drugs can trigger a dangerous overload: extremely high body temperature, muscle rigidity, and cardiovascular instability that can be fatal.[15][30]
Muscle breakdown
Severe overheating from MDMA can destroy muscle tissue and trigger dangerous blood clotting disorders.[30]
Psychological risks
Acute effects can include anxiety, paranoia, and depersonalization. No psychotic episodes have been reported at therapeutic doses in controlled studies.[7] MDMA was associated with elevated substance use disorder reports in pharmacovigilance data.[8]
Long-term heavy use is linked to small but measurable deficits in cognitive flexibility, working memory, and long-term memory recall.[23] Reduced brain volume in memory regions has been correlated with recent use intensity.[31] Whether these reflect permanent damage or reversible adaptation remains debated.[9][32]
Tolerance & dependence
Tolerance builds within a single session — supplemental doses produce weaker effects than the initial dose.[33] Serotonin stores deplete rapidly, and full recovery is estimated at several weeks to months.[22]
Physical withdrawal produces no classical symptoms on stopping.[34] Clinical trial participants showed no abuse liability at therapeutic doses,[11] though recreational use patterns show moderate dependence potential.[8]
Drug Interactions
MDMA's interaction risk comes from three mechanisms: serotonin flooding, cardiovascular strain, and enzyme inhibition.
The most dangerous combinations involve drugs that also raise serotonin. MAO inhibitors (phenelzine, tranylcypromine, moclobemide) block serotonin breakdown while MDMA simultaneously floods the synapse — the combination can produce fatal overheating, muscle breakdown, and organ failure.[35] Tramadol and high-dose dextromethorphan carry similar risk.[35]
SSRIs and SNRIs block MDMA's primary mechanism, substantially reducing its effects.[36] Stimulants — amphetamines, cocaine, methylphenidate — add to cardiovascular strain.[33] Other entactogens (MDA, 6-APB, mephedrone) compound serotonergic toxicity.
MDMA permanently disables the liver enzyme CYP2D6 for roughly two days. Any drug broken down by this enzyme — including many antidepressants, antipsychotics, and opioids — will accumulate to higher levels than usual during this window.[18][19]
Contraindications
11 knownConcurrent MAOI use is an absolute contraindication — the combination produces life-threatening serotonin syndrome.[35] Tramadol and DXM also carry documented risk of fatal serotonin syndrome.[35]
Relative contraindications include heart conditions, liver impairment (including dose-independent liver toxicity risk[29]), psychotic spectrum conditions, epilepsy,safety citation needed and pregnancy. Clinical trial participants underwent psychiatric medication washout before sessions.[11]
Harm Reduction[edit]
Forms & Identification
MDMA circulates as pressed tablets ("ecstasy"), loose crystals or powder ("molly"), and capsules. Form says nothing reliable about purity — testing consistently shows wide variation across all presentations. Reagent testing provides a useful first screen; quantitative testing services offer substantially more information where available.
Guidelines
- Test every batch with reagent kits at minimum; use quantitative testing services where available
- Start with a measured dose — do not eyeball powder
- Eat a light meal 2–3 hours before dosing to reduce nausea without slowing absorption
- Stay in a cool environment with access to fresh air
- Sip water or electrolyte drinks at a moderate pace — roughly 250–500 mL per hour of physical activity; do not overhydrate
- If redosing, take no more than half the initial dose and wait at least 90 minutes
- Have a sober companion present, especially at higher doses
- Allow at least several weeks between uses to permit serotonin recovery
Set & Setting
MDMA's effects are strongly shaped by environment. Hot, crowded spaces amplify both intensity and physiological risk — particularly overheating. Cool settings with trusted companions produce a qualitatively different and generally safer experience. Unresolved anxiety or interpersonal conflict can intensify during the experience rather than dissolve.
Aftercare & integration. The days after MDMA use often bring low mood, fatigue, irritability, and difficulty concentrating — a direct result of temporary serotonin depletion. Adequate sleep, nutrition, and gentle physical activity support recovery. Social connection and reflection can help process the emotional material that surfaced.
If low mood persists beyond a week, or the experience brought up difficult psychological material, professional support from a therapist familiar with substance experiences is appropriate. Journaling in the first 24–48 hours, while recall is fresh, can preserve insights for later integration.
Recovery & Support
Compulsive MDMA use typically involves escalating doses and shortening intervals — a pattern that produces diminishing effects and worsening comedowns as serotonin stores deplete. Recognizing this cycle is the first step. Gradual spacing of use, supported by honest self-assessment, is more sustainable than abrupt cessation for most people.
Professional support, peer communities, and harm reduction organizations can provide structure for those seeking to change their relationship with MDMA. If MDMA use is entangled with broader substance use or mental health difficulty, integrated treatment addressing all concerns produces better outcomes.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: body temperature hot to the touch through clothing, confusion or loss of consciousness, seizures, chest pain, or inability to stop muscle clenching signal a medical emergency — not normal discomfort. Sudden severe headache or visual disturbance may indicate dangerously low sodium.
Immediate steps:
- Call emergency services if the person is unconscious, seizing, extremely hot, or confused
- Move to a cool area and remove excess clothing
- Apply cool (not ice-cold) water to skin, especially neck and armpits
- If conscious, offer small sips of electrolyte solution — do not force fluids
- Do not leave the person alone
- Place an unconscious but breathing person in the recovery position
What to tell the dispatcher: Name the substance (MDMA/ecstasy), estimated amount, time taken, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from drug-related prosecution.
Legal Status[edit]
MDMA is controlled internationally under Schedule I of the United Nations Convention on Psychotropic Substances (1971). Most countries classify it as prohibited with no recognized medical use, though frameworks for therapeutic access have begun to emerge.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Emergency scheduling July 1985; permanent Schedule I March 1986.[13] FDA Breakthrough Therapy Designation for PTSD granted 2017;[37] NDA rejected August 2024.[6] No approved medical use as of April 2026. |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Possession: up to 7 years imprisonment. Supply: up to life imprisonment. |
| Australia | Schedule 8 (Controlled Drug) | Rescheduled from Schedule 9 effective 1 July 2023.[5] Prescribing permitted by authorized psychiatrists for PTSD under Authorised Prescriber scheme. First country to legally permit medical use. |
| Canada | Schedule III (CDSA) | Health Canada has granted Section 56 exemptions for therapeutic use in some clinical contexts; broad clinical access not yet available. |
| European Union | Nationally scheduled (varies) | Controlled under national law in all member states. International scheduling under UN Convention on Psychotropic Substances, Schedule I. Germany and the Netherlands developing research-use frameworks. |
| International | UN Convention Schedule I | Listed in Schedule I of the United Nations Convention on Psychotropic Substances (1971). |
Legal status changes frequently and varies significantly by jurisdiction. This information reflects the position as of April 2026 and does not constitute legal advice.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- rapid
- Tolerance reset
- 75 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- MDA · MDEA · 5-APB
Toxicity
Acute toxicity
No human lethal dose has been established. In clinical trials, MDMA has been administered to more than 1,100 individuals at doses up to 180 mg without drug-related serious adverse events.[33] MDMA had the largest number of adverse event reports of any psychedelic substance in the WHO global pharmacovigilance database (n = 1,573), with most events psychiatric in nature.[11]
Hyperthermia
Overheating is the primary cause of severe MDMA toxicity. MDMA disrupts the body's temperature regulation through multiple pathways, and this disruption is dramatically worsened by hot environments, physical exertion, and crowded spaces.[2][29] The combination of MDMA with sustained dancing in hot venues is the most common context for fatal overheating.
Hyponatremia
MDMA triggers inappropriate antidiuretic hormone release, which — combined with excessive water drinking — can dangerously dilute blood sodium levels and cause brain swelling.[34][35]
Suspected MDMA-related water intoxication with confusion or altered consciousness requires urgent medical attention. Treatment involves controlled saline administration and fluid restriction.[35]
Liver toxicity
MDMA can cause liver damage that appears days to weeks after use, sometimes independent of dose. Cases of acute liver failure requiring transplantation have been reported in young users.[36]
Heart and circulation
MDMA produces moderate increases in blood pressure and heart rate, with constriction of blood vessels including coronary arteries. These effects are substantially worsened by overheating. Phase 3 clinical trials found no dangerous heart rhythm changes.[6]
Serotonin syndrome
High doses or serotonergic drug combinations can trigger serotonin syndrome — a potentially fatal condition involving dangerously high body temperature, muscle rigidity, and cardiovascular instability.[21][37]
Muscle breakdown
Severe overheating from MDMA can cause muscle tissue breakdown and dangerous blood clotting disorders.[37]
Psychological risks
Acute psychological effects can include anxiety, paranoia, and depersonalization. No psychotic episodes have been reported at therapeutic doses in controlled studies.[10] MDMA was associated with elevated substance use disorder reporting in pharmacovigilance data.[11]
Long-term heavy use is associated with modest executive function deficits — a meta-analysis found small but significant impairments in cognitive flexibility, working memory updating, and long-term memory access.[31] Reduced brain volume in memory-related regions has been correlated with recent use intensity.[38] Whether these changes represent true neuronal damage or reversible adaptation remains debated.[14][39]
Tolerance & dependence
Tolerance develops within a single session — supplemental doses produce weaker effects than the initial dose.[40] MDMA rapidly depletes stored serotonin, and repeated use within short intervals yields diminishing returns. Full SERT recovery is estimated at several weeks to months.[30]
Physical withdrawal does not produce classical symptoms on cessation, though animal studies suggest a serotonergic dependence component.[41] Clinical trial participants showed no abuse liability at therapeutic doses and frequencies,[6] though recreational use patterns support moderate dependence potential.[11]
Drug Interactions
MDMA's interaction risk arises from three mechanisms: serotonin flooding, cardiovascular strain, and enzyme inhibition.
The most dangerous combinations involve drugs that independently increase serotonin levels. MAO inhibitors (phenelzine, tranylcypromine, moclobemide) block serotonin breakdown while MDMA simultaneously floods the synapse — the resulting serotonin toxicity can cause fatal overheating, muscle breakdown, and organ failure.[42] Tramadol and high-dose dextromethorphan carry analogous risk through their own serotonergic activity.[42]
SSRIs and SNRIs produce a more complex interaction: they block MDMA's primary mechanism, substantially reducing its effects.[24] This attenuation does not eliminate all risk, particularly with high-dose combinations.
Co-administration with stimulants (amphetamines, cocaine, methylphenidate) produces additive cardiovascular strain.[40] Combining MDMA with other entactogens (MDA, 6-APB, mephedrone) produces additive serotonergic toxicity.
MDMA's irreversible CYP2D6 inhibition means any drug metabolized by this enzyme — including many antidepressants, antipsychotics, and opioids — will reach elevated blood levels for approximately two days following MDMA use.[12][13]
Contraindications
11 knownConcurrent MAOI use is an absolute contraindication — the combination produces life-threatening serotonin toxicity.[42] Concurrent tramadol or DXM carries documented risk of fatal serotonin syndrome.[42]
Relative contraindications include heart conditions (MDMA's stimulant effects are worsened by overheating and exertion), liver impairment (reduced capacity to process toxic metabolites, with dose-independent liver toxicity documented[36]), psychotic spectrum conditions (limited safety data; Phase 3 trials excluded this population), epilepsy (potential seizure threshold lowering),safety citation needed and pregnancy (no safety data). Clinical trial participants underwent psychiatric medication washout before sessions.[6]
Harm Reduction[edit]
Forms & Identification
MDMA circulates as pressed tablets ("ecstasy"), loose crystals or powder ("molly"), and occasionally capsules. The distinction between these forms says nothing reliable about purity — analytical testing consistently shows wide variation across all presentations. Reagent testing provides a useful first screen but cannot detect every adulterant or confirm dose; quantitative testing services offer substantially more information where available.
Guidelines
- Test every batch with reagent kits at minimum; use quantitative testing services where available
- Start with a measured dose — do not eyeball powder
- Eat a light meal 2–3 hours before dosing to reduce nausea without slowing absorption
- Stay in a cool environment with access to fresh air
- Sip water or electrolyte drinks at a moderate pace — roughly 250–500 mL per hour of physical activity; do not overhydrate
- If redosing, take no more than half the initial dose and wait at least 90 minutes
- Have a sober companion present, especially at higher doses
- Allow at least several weeks between uses to permit serotonin recovery
Set & Setting
MDMA's effects are strongly shaped by environment. Hot, crowded spaces amplify both subjective intensity and physiological risk — particularly overheating. Cool, comfortable settings with trusted companions produce a qualitatively different and generally safer experience. Emotional state before dosing carries forward: unresolved anxiety or interpersonal conflict can intensify during the experience rather than dissolve.
Aftercare & integration. The days following MDMA use commonly involve low mood, fatigue, irritability, and difficulty concentrating — effects of temporary serotonin depletion. Adequate sleep, nutrition (particularly foods supporting serotonin production), and gentle physical activity support recovery. Social connection and reflective conversation can help process the emotional material that surfaced during the experience.
If low mood persists beyond a week, or if the experience brought up difficult psychological material, professional support from a therapist familiar with substance experiences is appropriate. Journaling during the first 24–48 hours, while recall is fresh, can preserve insights for later integration.
Recovery & Support
Compulsive MDMA use typically involves escalating doses and shortening intervals — a pattern that produces diminishing effects and worsening comedowns as serotonin stores deplete. Recognizing this cycle is the first step. Gradual spacing of use, supported by honest self-assessment of motivation and impact, is more sustainable than abrupt cessation for most people.
Professional support, peer communities, and harm reduction organizations can provide structure for those seeking to change their relationship with MDMA. If MDMA use is entangled with broader patterns of substance use or mental health difficulty, integrated treatment addressing all concerns produces better outcomes than addressing substances in isolation.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: body temperature hot to the touch through clothing, confusion or loss of consciousness, seizures, chest pain, or inability to stop muscle clenching distinguish a medical emergency from normal discomfort. Sudden severe headache or visual disturbance may indicate dangerously low sodium levels.
Immediate steps:
- Call emergency services if the person is unconscious, seizing, extremely hot, or confused
- Move to a cool area and remove excess clothing
- Apply cool (not ice-cold) water to skin, especially neck and armpits
- If conscious, offer small sips of electrolyte solution — do not force fluids
- Do not leave the person alone
- Place an unconscious but breathing person in the recovery position
What to tell the dispatcher: Name the substance (MDMA/ecstasy), estimated amount, time taken, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from drug-related prosecution.
Legal Status[edit]
MDMA is controlled internationally under Schedule I of the United Nations Convention on Psychotropic Substances (1971). Most national jurisdictions classify MDMA as a prohibited substance with no recognized medical use, though regulatory frameworks for therapeutic access have begun to emerge. Australia became the first country globally to permit medical prescribing in 2023.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Emergency scheduling July 1985; permanent Schedule I March 1986.[16] FDA Breakthrough Therapy Designation for PTSD granted 2017;[5] NDA rejected August 2024.[9] No approved medical use as of April 2026. |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Possession: up to 7 years imprisonment. Supply: up to life imprisonment. |
| Australia | Schedule 8 (Controlled Drug) | Rescheduled from Schedule 9 effective 1 July 2023.[8] Prescribing permitted by authorized psychiatrists for PTSD under Authorised Prescriber scheme. First country to legally permit medical use. |
| Canada | Schedule III (CDSA) | Health Canada has granted Section 56 exemptions for therapeutic use in some clinical contexts; broad clinical access not yet available. |
| European Union | Nationally scheduled (varies) | Controlled under national law in all member states. International scheduling under UN Convention on Psychotropic Substances, Schedule I. Germany and the Netherlands developing research-use frameworks. |
| International | UN Convention Schedule I | Listed in Schedule I of the United Nations Convention on Psychotropic Substances (1971). |
Frequently asked questions
What is MDMA?
MDMA is a substituted amphetamine classified as a stimulant and entactogen, acting as a substrate-type serotonin-preferential monoamine releaser. First synthesized at Merck in 1912, it received FDA Breakthrough Therapy Designation for PTSD in 2017; the agency declined approval in 2024.
How long does MDMA last?
Total duration by route of administration — Oral: 3 – 6 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for MDMA?
Psychedex publishes a dosage table for MDMA on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with MDMA?
The highest-severity documented interactions for MDMA: MAOIs (Lethal), 5-HTP, Tryptophan (Dangerous), Alpha-2 adrenergic receptor antagonist (Dangerous), Anticholinergics (Dangerous), Antihistamines (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is MDMA addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for MDMA: tolerance builds rapid; full reset takes 75 days; cross-tolerance develops with MDA, MDEA, 5-APB, 6-APB, methylone, mephedrone, amphetamine. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^abPifl C, Nagy G, Berényi S, et al. (2005) Pharmacological characterization of ecstasy synthesis byproducts with recombinant human monoamine transporters — Journal of Pharmacology and Experimental Therapeutics PMID:15831439
- [2]
- [3] ^abFreudenmann RW, Oxler F, Bernschneider-Reif S (2006) The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents — Addiction PMID:16911722
- [4] ^abBenzenhöfer U, Passie T (2010) Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin — Addiction doi:10.1111/j.1360-0443.2010.02948.x
- [5]
- [6] ^abcSingh B (2025) MDMA-Assisted Therapy for Post-Traumatic Stress Disorder: Regulatory Challenges and a Path Forward — CNS Drugs doi:10.1007/s40263-025-01162-y
references
- [1] ^abPifl C, Nagy G, Berényi S, et al. (2005) Pharmacological characterization of ecstasy synthesis byproducts with recombinant human monoamine transporters — Journal of Pharmacology and Experimental Therapeutics PMID:15831439
- [2]
- [3] ^abcFreudenmann RW, Oxler F, Bernschneider-Reif S (2006) The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents — Addiction PMID:16911722
- [4] ^abBenzenhöfer U, Passie T (2010) Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin — Addiction doi:10.1111/j.1360-0443.2010.02948.x
- [5] ^abcYazar-Klosinski BB, Mithoefer MC (2017) Potential Psychiatric Uses for MDMA — Clinical Pharmacology and Therapeutics doi:10.1002/cpt.565
- [6]